Trial site
Northeast Research Institute
Fleming Island, Florida 32003, United StatesNot linked to an institution yet
- 13running trials
- 11closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 24 trials
- Phase 11 trial
- Status
- Completed11 trials
- Active, not recruiting6 trials
- Recruiting5 trials
- Not yet recruiting2 trials
- Lead sponsor
- Novo Nordisk A/S22 trials
- Boehringer Ingelheim2 trials
Running trials
Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
NCT07931547· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587· Phase 1· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698· Phase 2· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· Phase 3· Novo Nordisk A/S· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
NCT06269107· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05394519· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
NCT05486065· Phase 2· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05352815· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
NCT05013229· Phase 3· Novo Nordisk A/S· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153· Phase 3· Novo Nordisk A/S· Source
Report an error